Acer Therapeutics





Please Login or Register

Login|Register FREE

Stock Price
Open: 19.29
Prev. Close: 19.49
Low/Hi: 18.62 - 19.33
52-Week: 5.70 - 22.63
Equity: 2,003
90-Day Avg: 28,537
Todays Stock Vol: 46.0
20-Day (HV): 80.9
52-Week (HV): 103.0
Div. Yield:
Earnings: 11-May (Est.)
P/E Ratio:
Market Cap: 146.1 M
Short Int Pct: 0.0%
Pct Held By Inst.: 4.9%
Stock Info
Type: Common
Sector: Healthcare
Industry: Biotechnology

ACER Company Events

Upcoming Events
Event Event Date Location Info
No Upcoming Events
Past Events
Event Event Date Location Info
30th Annual ROTH Conference Mar 13, 4:30 PM
Biotech Showcase 2018 Conference Jan 10, 2018
Cantor Fitzgerald Global Healthcare Conference Sep 26, 8:00 AM
Rodman & Renshaw 18th Annual Global Investment Conference Sep 12, 2016
Third International Conference on the Progress of Regenerative Medicine and Its Cultural Impact Apr 28, 2016 - Apr 30, 2016 Vatican City

Neil K. Warma, Opexa's President and Chief Executive Officer, has been invited to present

18th Annual BIO CEO and Investor Conference Feb 8, 2016 Louis XVI Room. The conference will be held at the Waldorf Astoria Hotel in New York, NY.

Neil K. Warma, President and Chief Executive Officer, will present

Rodman & Renshaw 17th Annual Healthcare Conference Dec 22, 2015
Analyst and Investor Event Nov 10, 2015 inNew York City,
BIO Investor Forum Oct 21, 2015 theParc 55 Hotel in San Francisco, California
Sidoti Emerging Growth Conference Sep 22, 2015
SeeThruEquity Fall Microcap Investor Conference Sep 10, 2015 Convene Grand Central, New York, New York
Biotechnology Industry Organization (BIO) 2015 International Convention in Philadelphia Jun 16, 1:45 PM
Marcum Microcap Conference- May 27-28, 2015, New York, New York, Grand Hyatt New York Hotel May 27, 10:00 AM

Mr. Warma will present as part of a panel discussion entitled, Discovering Breakthrough Opportunities in Life Sciences, How to Evaluate Early Stage and Pre-Revenue Life Science Companies

Boston CEO Biotechnology Conference May 26, 1:30 PM

Mr. Warma will present as part of a panel discussion entitled, The Importance of Patient Advocacy

Texas Life Science Forum May 20, 2015
China - U.S. Biopharmaceutical Innovative Collaboration Forum May 13, 10:30 AM

Mr. Warma will moderate a panel discussion entitled, From Preclinical to Phase III- Developing a Successful Clinical Development Program

Immune profiling of NMO patients receiving B-cell depleting therapy Apr 23, 4:00 PM

Opexa will present the results of a study conducted to characterize the cellular immune profile of NMO patients prescribed B-cell depleting therapy in comparison to those of healthy donors. The results showed that despite administration of B-cell depleting therapy, inflammation continued to persist as did the presence of activated T-cells. Opexa has a preclinical development program in NMO and IND enabling activities are currently being conducted with its drug development candidate, OPX-212. NMO is a rare autoimmune disorder designated as an Orphan disease by the FDA in which immune system cells and antibodies attack and destroy astrocytes, leading to secondary demyelination of neurons in the optic nerves and the spinal cord. NMO affects approximately 4,000-8,000 people in the U.S. and is an area with a significant unmet medical need. There is no cure for NMO and, worldwide, there are no approved therapies.

Wait, Before You Leave...

Want to Know More About ACER Earnings?

Receive your FREE email to get Wall Street expected earnings moves and daily upcoming earnings alerts!
Market Chameleon